NOT-HL-19-688: Notice of NHLBI Participation in PA-19-033 "Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)"

Notice of NHLBI Participation in PA-19-033 "Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)"

Notice Number: NOT-HL-19-688

Key Dates
Release Date: March 25, 2019

Related Announcements
PA-19-033

Issued by
National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PA-19-033 "Commercializing Understudied Proteins from the Illuminating the Druggable Genome Project (IDG) (R41/R42 Clinical Trial Not Allowed)".

The following sections of PA-19-033 have been modified (shown in italics):

Part 1. Overview Information

Components of Participating Organizations

National Institute of Dental and Craniofacial Research (NIDCR)
National Cancer Institute (NCI)
National Institute of Mental Health (NIMH)
National Library of Medicine (NLM)
National Center for Advancing Translational Sciences (NCATS)
National Heart, Lung, and Blood Institute (NHLBI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.121, 93.242, 93.879, 93.350, 93.393, 93.394, 93.395, 93.396, 93.399, 93.837, 93.938, 93.939, 93.840, 93.233

Section I. Funding Opportunity Description

The National Heart, Lung, and Blood institute (NHLBI) provides global leadership for research, training, and education programs to promote the prevention and treatment of heart, lung, blood, and sleep (HLBS) diseases. As such, the NHLBI has a significant interest in the development of technologies that will enable discoveries of the role of these understudied proteins in relevant pathways affecting HLBS disorders. The ultimate goal is the development of novel therapeutic and diagnostic modalities for the treatment of HLBS patients. Applicants are encouraged to contact program staff for consultation before submitting applications.

Section VII. Agency Contacts

Scientific/Research Contact(s)

Marc Charette, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0560
Email: [email protected]

Financial/Grants Management Contact(s)

Ann Marie Brasile Mejac
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8016
Email: [email protected]

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Marc Charette, Ph.D.
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0560
Email: [email protected]